We report a 61-year-old woman with a 1-year-history of widespread erythematous scaly patches and plaques as well as red/purplish to brownish confluent plaques. Ulcerated lesions with a purulent, hemorrhagic exudate and sharp elevated borders were located on the lower extremities. Diagnosis of granulomatous mycosis fungoides was supported by histopathologic findings showing an inflammatory reaction with epithelioid and large giant cells associated with features characteristic of mycosis fungoides. Immunohistochemical studies showed a T-helper phenotype of neoplastic cells (CD3+, CD4+, CD45RO+) with expression of the cytotoxic protein TIA-1. Molecular analysis of TCRγ gene demonstrated a monoclonal rearrangement in the lesional skin. After failure of conventional therapies, 6 cycles of gemcitabine treatment produced partial remission of cutaneous lesions and stable disease throughout a 12-month follow-up period, suggesting that gemcitabine is a promising chemotherapeutic agent for refractory mycosis fungoides.

Fargnoli, M., Peris, K., Francesconi, F., Cantonetti, M., Cerroni, L., Chimenti, S. (2002). Granulomatous mycosis fungoides responsive to gemcitabine. EUROPEAN JOURNAL OF DERMATOLOGY, 12(5), 479-481.

Granulomatous mycosis fungoides responsive to gemcitabine

CANTONETTI, MARIA;CHIMENTI, SERGIO
2002-01-01

Abstract

We report a 61-year-old woman with a 1-year-history of widespread erythematous scaly patches and plaques as well as red/purplish to brownish confluent plaques. Ulcerated lesions with a purulent, hemorrhagic exudate and sharp elevated borders were located on the lower extremities. Diagnosis of granulomatous mycosis fungoides was supported by histopathologic findings showing an inflammatory reaction with epithelioid and large giant cells associated with features characteristic of mycosis fungoides. Immunohistochemical studies showed a T-helper phenotype of neoplastic cells (CD3+, CD4+, CD45RO+) with expression of the cytotoxic protein TIA-1. Molecular analysis of TCRγ gene demonstrated a monoclonal rearrangement in the lesional skin. After failure of conventional therapies, 6 cycles of gemcitabine treatment produced partial remission of cutaneous lesions and stable disease throughout a 12-month follow-up period, suggesting that gemcitabine is a promising chemotherapeutic agent for refractory mycosis fungoides.
2002
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/15 - MALATTIE DEL SANGUE
Settore MED/06 - ONCOLOGIA MEDICA
English
Con Impact Factor ISI
EMTREE drug terms: antineoplastic agent; cytotoxic factor; cytotoxic protein TIA 1; etretinate; gemcitabine; recombinant alpha2b interferon; unclassified drug EMTREE medical terms: adult; article; bone marrow toxicity; cancer chemotherapy; case report; drug efficacy; drug induced disease; drug safety; female; follow up; granulomatous mycosis fungoides; histopathology; human; human tissue; mycosis fungoides; skin biopsy; skin lymphoma; skin tumor; treatment outcome MeSH: Antimetabolites, Antineoplastic; Biopsy, Needle; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Granuloma; Humans; Immunohistochemistry; Infusions, Intravenous; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome
Fargnoli, M., Peris, K., Francesconi, F., Cantonetti, M., Cerroni, L., Chimenti, S. (2002). Granulomatous mycosis fungoides responsive to gemcitabine. EUROPEAN JOURNAL OF DERMATOLOGY, 12(5), 479-481.
Fargnoli, M; Peris, K; Francesconi, F; Cantonetti, M; Cerroni, L; Chimenti, S
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/69212
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 2
social impact